Prelude Therapeutics and AbCellera have partnered to jointly discover, develop, and commercialise antibody-drug conjugate candidates (ADCs) for cancer treatment. The collaboration leverages Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development and AbCellera’s antibody discovery and development engine to generate novel precision ADCs. ADCs have been identified as a key innovation area by GlobalData, with multiple companies investing in these therapies. The most recent company to join this trend was MSD (Merck & Co), which signed a collaboration agreement with Daiichi Sankyo to develop and market three ADCs last month. Prelude will be responsible for the clinical development and global commercialisation, whilst AbCellera will lead the manufacturing activities for the ADCs. AbCellera will also have the option to co-promote the ADCs in the US, as per the 1 November press release. AbCellera generated $10.1m in revenue from discovery activity in Q2 2023, as per the company’s financials. AbCellera ...
Moderna has posted a reported net loss of $3.6bn in its Q3 earnings compared to a net income of $1bn during the same period last year, in line with the decreasing Covid-19-related revenues seen across the sector this year. For the quarter ended 1 October 2023, the company reported a diluted loss per share of $9.53. Revenues also saw a decline of 32% to $3.4bn from $5bn in the same quarter of the previous year. In its earnings release, Moderna attributed the drop in revenues to the expected decline in global revenue generated by the Covid-19 vaccine Spikevax. Spikevax revenues saw a 42% drop against the same quarter in 2022, from $3.1bn to $1.8bn. Still, the US market share to date of Spikevax grew to 45% from 36% in 2022, and Moderna anticipates 2024 revenues of approximately $4bn and return to growth in 2025. Part of this sales projection is ...
In a bid to further restructure operations, Sangamo plans to close its facility in Brisbane, California early in 2024, which will see 162 employees facing another round of layoffs. During the transition, the company will move its headquarters to its facility in Richmond, California, effective January 1, 2024. Sangamo will direct any freed resources towards advancing adeno-associated virus (AAV) capsid delivery technologies and its neurology epigenetic regulation portfolio via its investigational Nav1.7 and Prion disease therapies, said Sangamo CEO Sandy Macrae. Additionally, the company has decided to defer new investments for its Phase III Fabry and CAR-Treg studies and is instead actively seeking collaboration and investment partners for both programs. Sangamo is the latest to be swept in the wave of layoffs, following companies like NexImmune and Kinnate Biopharma, which sacked 53% and 70% of their respective workforces in September to redirect cash towards priority projects. In a conference call ...
Pfizer’s Litfulo (ritlecitinib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat severe alopecia areata in patients aged 12 years and older. Affecting approximately 147 million people globally, alopecia areata is an autoimmune disease characterised by patchy or complete hair loss on the scalp, face or body. The condition can develop at any age and nearly 20% of patients are diagnosed before the age of 18. Litfulo, which is a one-daily oral kinase inhibitor, works by blocking the activity of enzymes in the body involved in inflammation at the hair follicle. This reduces the inflammation, leading to hair regrowth in patients with alopecia areata. The MHRA’s decision on the drug was supported by positive results from the phase 2b/3 ALLEGRO trial, which evaluated Litfulo in patients aged 12 years and older with 50% or more scalp hair loss, including those with total scalp and body ...
Dive Brief CooperCompanies bought some of Cook Medical’s obstetrics, doppler monitoring and gynecology surgery products for $300 million, the companies announced on Wednesday. The acquisition follows an attempt by Cooper to acquire Cook’s reproductive health business, which was scrapped amid scrutiny from the Federal Trade Commission. The assets included in the purchase do not include any of the fertility products the companies had discussed in the original deal, Cooper said. Dive Insight Cooper paid $200 million upfront and will pay two more annual installments of $50 million each. In exchange, it will acquire Cook’s Bakri postpartum balloon, cervical ripening balloon, doppler blood flow monitor portfolio and other surgical products. Cooper CEO Al White said in the deal announcement that the acquired devices “are highly synergistic” with the company’s current portfolio and will strengthen its position in fertility and women’s health. San Ramon, California-based Cooper’s surgery segment includes fertility, gynecology and ...
One in seven people in the US reported having had long Covid by the end of 2022, suggests a large-scale investigation of long Covid and symptom prevalence by academics at UCL and Dartmouth. Having had long Covid is associated with anxiety and low mood, as well as an increased likelihood of continued physical mobility problems and challenges with memory, concentration or understanding, according to the findings published in PLOS ONE. The risk of anxiety and low mood appeared to be lower for those who have been vaccinated, including for those who have had long Covid. Alex Bryson, Co-Author, Professor, UCL Social Research Institute, said, “Little is known about long Covid and its impact on health and wellbeing, but there is a growing body of evidence that many people experience persistent and concerning symptoms. Here, we have found that long Covid continues to affect millions of people in the US, with ...
Only 21% of primary care physicians feel they are fairly compensated, according to a new report from Pearl Health. However, primary care physicians who participate in an ACO were 56% more likely than non-ACO participants to believe they are paid fairly. ACO participants were also 15% more likely to believe that the way they generate revenue allows them to deliver holistic care. By KATIE ADAMS Only 21% of primary care physicians feel they are fairly compensated, according to a new report released by Pearl Health, a tech company that helps independent physician practices participate in value-based care models. For the report, the company collected survey responses from 202 primary care physicians from July 11 to October 9. Recent data shows that the three physician specialties with the lowest compensation rates are preventive, general practice and family practice. There is some irony to this given the fact that quality primary care ...
Don Tracy, Associate Editor The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond. Image Credit: Adobe Stock Images/Dimid The launch of multiple glucagon-like peptide (GLP-1) drugs for weight loss—such as Ozempic, Wegovy, and Mounjaro—is expected to cause a major shakeup in the stock market, as millions of Americans are set to shed hundreds of millions of pounds over the next decade while reshuffling trillions of dollars in the process, according to expert analysis. Not only have these treatments helped patients shed a significant amount of pounds, but they have also shown efficacy treating other conditions as well. A recent drug trial by Novo Nordisk found that semaglutide, the active ingredient in Ozempic and Wegovy, could help people with kidney failure as well. As shares of Novo Nordisk and Mounjaro developer Eli Lilly increase, dialysis ...
By Kate Goodwin Pictured: A researcher at work in a Novavax laboratory/Novavax, Patrick Siebert Combination vaccines are nothing new for the healthcare industry. Childhood vaccines, as well as a single shot for tetanus, diphtheria and pertussis for adults, have long been combined for ease of administration and increased compliance rates. Now, as vaccines for COVID-19 and, for older people, RSV and pneumococcal disease join the annual flu shot as routine care recommendations for adults, healthcare professionals are increasingly concerned over getting the word out, vaccine fatigue and logistical hurdles. Biopharma companies are betting there will be a market for vaccines that combine protection against two or more diseases in a single jab. Benefit to the Population “The data are pretty unequivocal that when there are combo vaccines available, people generally prefer [them],” said Andrea C. Love, an immunologist and microbiologist and founder of the Unbiased Science Podcast. Love pointed out ...
By Tyler Patchen While Moderna’s total revenue for the third quarter beat Wall Street expectations, the vaccine maker on Thursday posted a loss as demand for its COVID-19 shots declined. Moderna announced that overall sales for the third quarter were $1.8 billion, down from $3.4 billion in the same period of 2022. Net product sales for Moderna were also down 44% from last year due to a “lower sales volume” but partially offset by a higher average selling price the company unveiled. In the third quarter, Moderna said it saw charges of $1.3 billion for “inventory writedowns,” which were related to “excess and obsolete COVID-19 products.” Investors were not pleased as Moderna’s stock price fell over 15% pre-market on Thursday. “Through this quarter, we demonstrated our ability to increase share in the U.S. market, and we now expect this year’s vaccination rate to be similar to last fall,” Moderna CEO ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.